Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies

Buddadasari Snehitha

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

Mopuri Jyothsna

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

Akula Ruchitha Sai

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

Binaya Sapkota

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

Bandaru Revanth

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

K Somasekhar Reddy

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

Bhupalam Pradeep Kumar *

Department of Pharmacology, Raghavendra Institute of Pharmaceutical Education and Research (RIPER) – Autonomous, KR Palli Cross, Chiyyedu (Post), Anantapur, Andhra Pradesh– 515721, India.

*Author to whom correspondence should be addressed.


A new era in cancer treatment has begun with the development of monoclonal antibodies (mAbs), which have improved therapeutic results and precision targeting to a great extent. Specialized monoclonal antibodies (mAbs) are engineered to attach specifically to cancer antigens, allowing them to directly target tumor cells and influence the immune system for therapeutic purposes. Significant advancements in this field include the approval and clinical efficacy of mAbs that target B-cell lymphomas and HER2-positive breast cancer. Notable cases like as trastuzumab and rituximab highlight the real benefits of these treatments, which include better patient outcomes and survival rates.

Furthermore, by triggering the body's immunological defenses against cancer cells, immune checkpoint inhibitors like pembrolizumab have completely changed the way that cancer is treated. For individuals with previously difficult-to-treat illnesses, this innovative technique has shown extraordinary success across a variety of cancer types.

Innovative approaches including antibody-drug conjugates and bispecific antibodies have also been produced by ongoing developments in mAb engineering. These technical miracles improve the overall safety profile of monoclonal antibodies (mAb) therapeutics by compensating for off-target effects and optimizing therapeutic efficacy. There are still issues, such as toxicity and the emergence of drug resistance, in spite of significant progress. Even Nevertheless, continued research and development initiatives highlight the enormous potential of monoclonal antibodies in customized cancer treatment plans. These advances promise a better future for cancer patients everywhere by highlighting the quick evolution of cancer therapies and encouraging increased research and innovation in this vital area of medicine.

Keywords: Immunotherapies, Her2-positive breast cancer, targeted antigens, oncology, Car T Cell treatment

How to Cite

Snehitha, B., Jyothsna , M., Sai , A. R., Sapkota , B., Revanth , B., Reddy, K. S., & Kumar, B. P. (2024). Advancing Cancer Therapy: A Review of Recent Progress in Monoclonal Antibodies. Asian Journal of Advances in Research, 7(1), 159–173.


Download data is not yet available.


Afrah AK, Seta AS. An Immunohistochemical Expressions of BAD, MDM2, and P21 in Oral Squamous Cell Carcinoma. J Bagh Coll Dentistry 2016;28(2):34-39.

Rodríguez‐Antona C, Taron M. Pharmacogenomic biomarkers for personalized cancer treatment. J Intern Med. 2015 Feb;277(2):201–17.

Sun H, Yang H, Mao Y. Personalized treatment for hepatocellular carcinoma in the era of targeted medicine and bioengineering. Front Pharmacol. 2023 May 5;14:1150151.

Tarcic G, Yarden Y. Antibody-Mediated Receptor Endocytosis: Harnessing the Cellular Machinery to Combat Cancer. In: Yarden Y, Tarcic G, editors. Vesicle Trafficking in Cancer [Internet]. New York, NY: Springer New York; 2013 [cited 2024 Apr 11]. p. 361–84 Available: 4614-6528-7_17

Marin-Acevedo JA, Kimbrough EO, Lou Y. Next generation of immune checkpoint inhibitors and beyond. J HematolOncolJHematol Oncol. 2021 Mar 19;14(1):45.

Marshall HT, Djamgoz MBA. Immuno- Oncology: Emerging Targets and Combination Therapies. Front Oncol [Internet]. 2018 Aug 23 [cited 2024 Apr11];8 Available: ls/oncology/articles/10.3389/fonc.2018.003 15/full

Al-Dewik NI, Younes SN, Essa MM, Pathak S, Qoronfleh MW. Making Biomarkers Relevant to Healthcare Innovation and Precision Medicine.Processes.2022 Jun;10(6): 1107.

Fatima I, Rahdar A, Sargazi S, Barani M, Hassanisaadi M, Thakur VK. Quantum Dots: Synthesis, Antibody Conjugation, and HER2-Receptor Targeting for Breast Cancer Therapy. J FunctBiomater. 2021 Dec;12(4):75.

Li W, Guo H, Li L, Zhang Y, Cui J. The promising role of antibody drug conjugate in cancer therapy: Combining targeting ability with cytotoxicity effectively. Cancer Med. 2021 Jul;10(14):4677–96.

Thakur A, Huang M, Lum LG. Bispecific antibody based therapeutics: Strengths and challenges. Blood Rev. 2018 Jul 1;32(4):339–47.

Little M. Generation, Structure, and Function of Antibodies. In: Antibodies for Treating Cancer [Internet]. Cham: Springer International Publishing; 2021 [cited 2024 Apr 11]:35–46 Available: 978-3-030-72599-0_4

Sela-Culang I, Kunik V, Ofran Y. The Structural Basis of Antibody-Antigen Recognition. Front Immunol [Internet]. 2013 Oct 8 [cited 2024 Apr 11];4 Available: ls/immunology/articles/10.3389/fimmu.201 3.00302/full

Megha KB, Mohanan PV. Role of immunoglobulin and antibodies in disease management. Int J Biol Macromol. 2021 Feb 1;169:28–38.

Gómez Román VR, Murray JC, Weiner LM. Chapter 1 - Antibody-Dependent Cellular Cytotoxicity (ADCC). In: Ackerman ME, Nimmerjahn F, editors. Antibody Fc [Internet]. Boston: Academic Press; 2014 [cited 2024 Apr 11]:1–27 Available: cle/pii/B9780123948021000017

Zahavi D, Weiner L. Monoclonal Antibodies in Cancer Therapy. Antibodies. 2020 Sep;9(3):34.

Taefehshokr N, Baradaran B, Baghbanzadeh A, Taefehshokr S. Promising approaches in cancer immunotherapy. Immunobiology. 2020 Mar 1;225(2):151875.

Behl A, Wani ZA, Das NN, Parmar VS, Len C, Malhotra S, et al. Monoclonal antibodies in breast cancer: A critical appraisal. Crit Rev Oncol Hematol. 2023 Mar 1;183:103915.

Rasheed RH, Al-Delaimi T N, Khalil AA. Immunohistochemical Expression of CD20, CD43, and CD79 in Burkitt’s Lymphoma. The N Iraqi J Med April 2010; 6(2): 66-69

Tam KY, Leung KCF, Wang YXJ. Chemoembolization agents for cancer treatment. Eur J Pharm Sci. 2011 Sep 18;44(1):1–10.

Pelizzaro F, Haxhi S, Penzo B, Vitale A, Giannini EG, Sansone V,et al. Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment. Front Oncol [Internet]. 2022 Jan 31 [cited 2024 Apr 11];12 Available: y/articles/10.3389/fonc.2022.822507/full

Neves H, Kwok HF. Recent advances in the field of anti-cancer immunotherapy. BBA Clin. 2015 Jun 1;3:280–8.

Thakkar S, Sharma D, Kalia K, Tekade RK. Tumor microenvironment targeted nanotherapeutics for cancer therapy and diagnosis: A review. Acta Biomater. 2020 Jan 1;101:43–68.

Tzankov A, Zimpfer A, Pehrs AC, Lugli A, Went P, Maurer R, et al. Expression of B- Cell Markers in Classical Hodgkin Lymphoma: A Tissue Microarray Analysis of 330 Cases. Mod Pathol. 2003 Nov 1;16(11):1141–7.

Lucchini E, Zaja F, Bussel J. Rituximab in the treatment of immune thrombocytopenia: What is the role of this agent in 2019? Haematologica. 2019 Jun;104(6):1124–35.

Taylor RP, Lindorfer MA. Drug Insight: The mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis. Nat Clin PractRheumatol. 2007 Feb;3(2):86–95.

Selepe CT, Dhlamini KS, Tshweu L, Moralo M, Kwezi L, Ray SS, et al. Trastuzumab‐based nanomedicines for breast cancer therapy: Recent advances and future opportunities. Nano Sel. 2024 Feb 17;2300191.

Akbari V, Chou CP, Abedi D. New insights into affinity proteins for HER2-targeted therapy: Beyond trastuzumab. BiochimBiophys Acta BBA - Rev Cancer. 2020 Dec 1;1874(2):188448.

Raghani NR, Chorawala MR, Mahadik M, Patel RB, Prajapati BG, Parekh PS. Revolutionizing cancer treatment: comprehensive insights into immunotherapeutic strategies. Med Oncol. 2024 Jan 9;41(2):51.

Su SC, Lin CW, Yang WE, Fan WL, Yang SF. The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies. Expert Opin Ther Targets. 2016 May 3;20(5):551–66.

Vasiljeva O, Menendez E, Nguyen M, Craik CS, Michael Kavanaugh W. Monitoring protease activity in biological tissues using antibody prodrugs as sensing probes. Sci Rep. 2020 Apr 3;10(1):5894.

Yang D, Severin GW, Dougherty CA, Lombardi R, Chen D, Van Dort ME, et al. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging. Oncotarget. 2016 Oct 8;7(45):73912–24.

The Best IgG Subclass for the Development of Therapeutic Monoclonal Antibody Drugs and their Commercial Production: A Review - ProQuest [Internet]. [cited 2024 Apr 11] Available: ew/537d50af38a14eabc7ecc92bb8c6db92/ 1?pq-origsite=gscholar&cbl=54870

Elter A, Yanakieva D, Fiebig D, Hallstein K, Becker S, Betz U, et al. Protease- Activation of Fc-Masked Therapeutic Antibodies to Alleviate Off-Tumor Cytotoxicity. Front Immunol [Internet]. 2021 Aug 3 [cited 2024 Apr 11];12 Available: ls/immunology/articles/10.3389/fimmu.202 1.715719/full

Denny WA. Prodrug strategies in cancer therapy. Eur J Med Chem. 2001 Aug 1;36(7):577–95.

Esperante D, Flisser A, Mendlovic F. The many faces of parasite calreticulin. Front Immunol [Internet]. 2023 Mar 10 [cited 2024 Apr 11];14 Available: ls/immunology/articles/10.3389/fimmu.202 3.1101390/full

Gauthier M, Laroye C, Bensoussan D, Boura C, Decot V. Natural Killer cells and monoclonal antibodies: Two partners for successful antibody dependent cytotoxicity against tumor cells. Crit Rev Oncol Hematol. 2021 Apr 1;160:103261.

Snyder KM, Hullsiek R, Mishra HK, Mendez DC, Li Y, Rogich A, et al. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells. Front Immunol [Internet]. 2018 Dec 6 [cited 2024 Apr 11];9 Available: ls/immunology/articles/10.3389/fimmu.201 8.02873/full

Prager I, Watzl C. Mechanisms of natural killer cell-mediated cellular cytotoxicity. J Leukoc Biol. 2019 Jun 1;105(6):1319–29.

Barbet J, Bardiès M, Bourgeois M, Chatal JF, Chérel M, Davodeau F, et al. Radiolabeled Antibodies for Cancer Imaging and Therapy. In: Chames P, editor. Antibody Engineering [Internet]. Totowa, NJ: Humana Press; 2012 [cited 2024 Apr 11]. p. 681–97. (Methods in Molecular Biology; vol. 907).

Available: 978-1-61779-974-7_38

Muntjewerff EM, Meesters LD, Bogaart G van den, Revelo NH. Reverse Signaling by MHC-I Molecules in Immune and Non- Immune Cell Types. Front Immunol [Internet]. 2020 Dec 15 [cited 2024 Apr 11];11 Available: ls/immunology/articles/10.3389/fimmu.202 0.605958/full

Dustin ML. The Immunological Synapse. Cancer Immunol Res. 2014 Nov 2;2(11):1023–33.

Jaiswal S, Chao MP, Majeti R, Weissman IL. Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 2010 Jun 1;31(6):212–9.

Wang W. NK cell-mediated antibody- dependent cellular cytotoxicity in cancer immunotherapy. Front Immunol [Internet]. 2015 [cited 2024 Apr 11];6.

Available: cle/10.3389/fimmu.2015.00368/abstract

Liu R, Oldham RJ, Teal E, Beers SA, Cragg MS. Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment. Antibodies. 2020 Dec;9(4):64.

Saunders KO. Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life. Front Immunol. 2019 Jun 7;10:1296.

Vietzen H, Danklmaier V, Zoufaly A, Puchhammer-Stöckl E. High-affinity FcγRIIIa genetic variants and potent NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) responses contributing to severe COVID-19. Genet Med. 2022 Jul 1;24(7):1449–58.

Del Bano J, Chames P, Baty D, Kerfelec B. Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward? Antibodies. 2016 Mar;5(1):1.

Golay J, Taylor RP. The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs. Antibodies. 2020 Dec;9(4):58.

Bojarczuk K, Siernicka M, Dwojak M, Bobrowicz M, Pyrzynska B, Gaj P, et al. B- cell receptor pathway inhibitors affect CD20 levels and impair antitumor activity of anti-CD20 monoclonal antibodies. Leukemia. 2014 May;28(5):1163–7.

Wang H, Liu Y, Li ZY, Fan X, Hemminki A, Lieber A. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood. 2010 Jan 21;115(3):592–600.

Dhar R, Seethy A, Singh S, Pethusamy K, Srivastava T, Talukdar J, et al. Cancer immunotherapy: Recent advances and challenges. J Cancer Res Ther. 2021 Sep;17(4):834.

Schirrmacher V. From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review). Int J Oncol. 2019 Feb 1;54(2):407–19.

Lee L, Gupta M, Sahasranaman S. Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy. J Clin Pharmacol. 2016 Feb;56(2):157–69.

Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018 Sep 1;62:29–39.

Myers DR, Wheeler B, Roose JP. MTOR and other effector kinase signals that impact T cell function and activity. Immunol Rev. 2019 Sep;291(1):134–53.

Zhang H, Dai Z, Wu W, Wang Z, Zhang N, Zhang L, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021 Jun 4;40(1):184.

Raskov H, Orhan A, Christensen JP, Gögenur I. Cytotoxic CD8+ T cells in cancer and cancer immunotherapy. Br J Cancer. 2021 Jan;124(2):359–67.

Kaeuferle T, Krauss R, Blaeschke F, Willier S, Feuchtinger T. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation. J HematolOncolJHematol Oncol. 2019 Feb 6;12(1):13.

Katiyar V, Chesney J, Kloecker G. Cellular Therapy for Lung Cancer: Focusing on Chimeric Antigen Receptor T (CAR T) Cells and Tumor-Infiltrating Lymphocyte (TIL) Therapy. Cancers. 2023 Jan;15(14):3733.

GeukesFoppen MH, Donia M, Svane IM, Haanen JBAG. Tumor-infiltrating lymphocytes for the treatment of metastatic cancer. Mol Oncol. 2015 Dec 1;9(10):1918–35.

Park CG, Hartl CA, Schmid D, Carmona EM, Kim HJ, Goldberg MS. Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases. Sci Transl Med. 2018 Mar 21;10(433):eaar1916.

Martinez M, Moon EK. CAR T Cells for Solid Tumors: New Strategies for Finding, Infiltrating, and Surviving in the Tumor Microenvironment. Front Immunol. 2019 Feb 5;10:128.

Riley RS, June CH, Langer R, Mitchell MJ. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019 Mar;18(3):175–96.

Aikins ME, Xu C, Moon JJ. Engineered Nanoparticles for Cancer Vaccination and Immunotherapy. Acc Chem Res. 2020 Oct 20;53(10):2094–105.

Saleh RO, Ibrahim FM, Pallathadka H, Kaur I, Ahmad I, Ali SHJ, et al. Nucleic acid vaccines-based therapy for triple- negative breast cancer: A new paradigm in tumor immunotherapy arena. Cell BiochemFunct. 2024;42(3): e3992.

Zhu S, Zhang T, Zheng L, Liu H, Song W, Liu D, et al. Combination strategies to maximize the benefits of cancer immunotherapy. J HematolOncolJHematol Oncol. 2021 Sep 27;14(1):156.

Eder JP, Vande Woude GF, Boerner SA, LoRusso PM. Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer. Clin Cancer Res. 2009 Apr 1;15(7):2207–14.

Rosenberg AS, Sauna ZE. Immunogenicity assessment during the development of protein therapeutics. J Pharm Pharmacol. 2018 May 1;70(5):584–94.

Kroschinsky F, Stölzel F, von Bonin S, Beutel G, Kochanek M, Kiehl M, et al. New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management. Crit Care. 2017 Apr 14;21(1):89.

Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol. 2021 Dec 20;39(36):4073–126.

Diesendruck Y, Benhar I. Novel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges. Drug Resist Updat. 2017 Jan 1;30: 39–47.

Bertolaccini L, Casiraghi M, Uslenghi C, Maiorca S, Spaggiari L. Recent advances in lung cancer research: Unravelling the future of treatment. Updat Surg [Internet]. 2024 Apr 6 [cited 2024 Apr 11] Available: 024-01841-3